GLIRIDE 1mg glimepiride tablets 1mg blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

glimepiride, Quantity: 1 mg

Disponible depuis:

Micro Labs Pty Ltd

DCI (Dénomination commune internationale):

Glimepiride

forme pharmaceutique:

Tablet, uncoated

Composition:

Excipient Ingredients: lactose monohydrate; microcrystalline cellulose; iron oxide red; povidone; sodium lauryl sulfate; sodium starch glycollate type A; magnesium stearate

Mode d'administration:

Oral

Unités en paquet:

blister pack of 30's [15's X 2] in Monocarton

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.

Descriptif du produit:

Visual Identification: Pink coloured capsule shaped tablet with embossing GM & 1 with score line on one side and score line on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2016-08-03

Résumé des caractéristiques du produit

1
AUSTRALIAN
PRODUCT INFORMATION- GLIRIDE TABLETS (GLIMEPIRIDE)
1
NAME OF THE MEDICINE
Glimepiride
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
GLIRIDE tablets contain 1 mg, 2 mg, 3 mg or 4 mg of glimepiride.
Excipient with known effect:
Contains sugars as lactose monohydrate
For a full list of excipients, see section 6.1 LIST OF EXCIPIENTS.
3
PHARMACEUTICAL FORM
GLIRIDE tablets
•
1.0 mg: Pink coloured capsule shaped tablet with embossing “GM” &
“1” with score line
on one side and score line on the other side.
•
2.0 mg: Pale green coloured capsule shaped tablet with embossing
“GM” & “2” with
score line on one side and score line on the other side.
•
3.0 mg: Pale yellow coloured capsule shaped tablet with embossing
“GM” & “3” with
score line on one side and score line on the other side.
•
4.0 mg: Light blue coloured capsule shaped uncoated tablet with
embossing “GM” & “4”
with score line on one side and score line on the other side.
4
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
GLIRIDE is indicated as an adjunct to diet, exercise and weight loss,
to lower the
blood glucose in patients with non-insulin-dependent (type 2) diabetes
mellitus.
4.2 DOSE AND METHOD OF ADMINISTRATION
In the management of type 2 diabetes mellitus, administration of an
oral antidiabetic
agent is not a substitute for appropriate dietary control.
In initiating treatment for type 2 diabetes mellitus, diet should be
emphasised as the
primary form of treatment. Caloric restriction and weight loss are
essential in the
2
obese
diabetic
patient.
Proper
dietary
management
alone
may
be
effective
in
controlling the blood glucose and symptoms of hyperglycaemia. The
importance of
regular physical activity should also be stressed, and cardiovascular
risk factors
should be identified and corrective measures taken where possible.
If this treatment program fails to reduce symptoms and/or blood
glucose, the use of
an oral sulfonylurea should be considered. Use of GLIRIDE must be
viewed by both
the physician and pati